Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — SPAC Merger (May 2021)
77 slides from Jasper Therapeutics's SPAC merger presentation, May 6, 2021
Slide 1: Enabling Cures with Hematopoietic Stem Cell Transplants
CONFIDENTIAL Enabling Cures with Hematopoietic Stem Cell Transplants April 2021
Slide 2: Safe Harbor Statement
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Safe Harbor Statement 2 About this Presentation This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making th eir own evaluation with respect to the proposed business combination (the “Propo
Slide 3: Jasper and Amplitude Add Significant Capital to Advance a Leader in HSC Transplant
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Jasper and Amplitude Add Significant Capital to Advance a Formidable Leader in Hematopoietic Stem Cell Transplant for a Range of Indications 3 Creating well funded leader in hematopoietic stem cells for a range of indications Multiple near - term milesto
Slide 4: Metalmark Capital and Avego Healthcare Capital Bring Strong Track Record
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Metalmark Capital and Avego Healthcare Capital Bring a Strong Track Record and Broad Suite of Capabilities 4 Metalmark’s expertise in executing transactions coupled with Avego’s deep industry knowledge creates a unique level of expertise in pursuing acqu
Slide 5: Amplitude Healthcare Acquisition: Management, Board of Directors, and Advisors
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Amplitude Healthcare Acquisition : Management, Board of Directors, and Advisors 10 seasoned investors from Metalmark and Avego to work with Amplitude 5 Bala Venkataraman - CEO & Director ● Founding Partner at Avego ● Most recently Co - Founder & Executiv
Slide 6: Jasper Expected Milestones
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Jasper Expected Milestones • Q2 2021 – JSP191 AML/MDS Phase 1a top line 90 - day data • Q2 2021 – JSP191 AML/MDS open enrollment of Phase 1b expansion • Q4 2021 – JSP191 Autoimmune IND filing for Phase 1a pilot study • Q4 2021 – Engineered Stem Cell Plat
Slide 7: PIPE Overview
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. PIPE Overview 7 Type of offering Private Investment in Public Equity (PIPE) Target Company Jasper Therapeutics, Inc. SPAC sponsor Amplitude Healthcare Acquisition Corp. Estimated size of offering $100mm Commitment from Jasper existing shareholders $25mm
Slide 8: De-SPAC Structure and Transaction Overview
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. De - SPAC Structure and Transaction Overview 8 Sources and uses ($mm) Pro forma ownership (shares in mm) Note: Promote vests 60% at close (1.5mm shares), 20% at $15 (0.5mm shares) and 20% at $18 (0.5mm shares). Three years to hit tri gger or on CoC above
Slide 9: Jasper Therapeutics Highlights
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Jasper Therapeutics Highlights: Science Based on Hematopoietic Stem Cells and Their Biology 9 • Platform of cell engineered programs to increase the cure rate of allogeneic and gene therapy grafts as well as improve their safety • Multiple in - vitro and
Slide 10: Management Team and Scientific Advisory Board
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Management Team and Scientific Advisory Board: Drug Development & Company Building Track Record and Experts in the Field 10 MANAGEMENT William Lis , Executive Chair & CEO Kevin N. Heller , Executive Vice President, Research and Development Jeet Mahal , C
Slide 11: Unmet Medical Need: HSCT Most Powerful Cure, Yet Underutilized
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Unmet Medical Need: Hematopoietic Stem Cell Transplants (HSCT) Most Powerful Form of Disease Cure, Yet Remain Underutilized 11 Jasper Therapeutics could exponentially expand the eligible patient population for both allogeneic and autologous gene edited h
Slide 12: Jasper's Science Focused on the Stem Cell, Targeting CD117
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Jasper’s Science is Focused on the Stem Cell, Targeting Stem Cell Factor Receptor & Expanding to Novel Cell Engineering 12 • Stem Cell Factor (SCF) / Stem Cell Factor Receptor (CD117) interaction required for stem cell survival • JSP191 blocks SCF signal
Slide 13: Jasper's Expanding Pipeline
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Jasper’s Expanding Pipeline 13 PROGRAM RESEARCH IND - ENABLING CLINICAL COMMERCIAL JSP191 CONDITIONING AML/ MDS SCID Autoimmune (Lupus, MS, Scleroderma) Fanconi’s Anemia Sickle Cell Disease Gene Therapy (X - SCID) Jasper eHSC GRAFTS Thalassemias Sickle C
Slide 14: Unique and Differentiated JSP191 Properties Compared to Other CD117 Antibodies
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Unique and Differentiated JSP191 Properties Compared to All Other CD117 Antibodies Only anti - CD117 antibody that inhibits stem cell factor survival signal resulting in targeted depletion • Only JSP191 shows in - vivo single agent depletion • JSP191 SCF
Slide 15: JSP191's First Clinical POC in SCID
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191’s First Clinical POC in Ultra Orphan Indication, Severe Combined Immunodeficiency (SCID) SCID is a lethal genetic immune disorder. HCT is the only proven cure, without it most infants die before the age of two year s. 15 Jasper SCID Clinical Trial
Slide 16: JSP191 Conditioning in SCID HCT Demonstrates Durable Naive T-cell Production
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 Conditioning in SCID HCT Demonstrates Durable Naive T - cell Production and Immune System Reconstitution 16 Naïve CD4 T cell production post - cell infusion A. No Conditioning (Matched Cohort Patient) B. JSP191 Conditioning *85 /µL *Expected Level
Slide 17: JSP191 is Advancing in AML and MDS
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 is Advancing in AML and MDS, a Large Opportunity for Curative HCT with Non - Toxic Conditioning 17 AML and MDS are clonal myeloid malignancies and diseases of elderly with high mortality HCT is a SOC curative procedure: ~11,000 G7 HCTs in 2019, bu
Slide 18: JSP191 AML/MDS Study: Ongoing Study in MRD Positive Patients
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 AML/ MDS Study: Ongoing Study in MRD Positive Patients Not Eligible for Full Myeloablative Conditioning 18 MRD Positive AML/MDS Patients Not Eligible for Standard Myeloablative Regimens (HCT - Cl >2) ClinicalTrials.gov NCT04429191 DOSE FINDING DOS
Slide 19: MDS/AML: Neutropenia Followed by Donor Cell Engraftment
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL MDS/AML: Neutropenia Followed by Donor Cell Engraftment Suggests Successful Myeloablation Using JSP191/TBI/Flu Combination 0 28 56 90 0 10 70 80 90 100 Days after HCT % D o n o r d e r i v e d i n P B M C Total Blood Chimerism 0 28 56 90 0 20 40 60 80 10
Slide 20: JSP191 Conditioning Leads to Successful Transplant and MRD Negative Status
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. CONFIDENTIAL: JSP191 Conditioning Leads to Successful Transplant and Conversion to MRD Negative Status/ MRD Reduction in First AML & MDS Patients 20 N o treatment related SAEs MRD Positive AML/MDS Patients Not Eligible for Standard Myeloablative Regimens
Slide 21: Expected Full Donor Chimerism With TBI/Flu Alone is ~60%
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Expected Full Donor Chimerism With TBI/Flu Alone is ~60% and Lack of Full Donor Chimerism is Associated with Poor Survival 21 200 cGy TBI + Flu Alone 62% of patients demonstrated full chimerism after conditioning with 2 Gy TBI/Flu 1 Eggimann L, Girsberge
Slide 22: JSP191 MDS/AML Paths to Regulatory Approvals
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 MDS/AML Paths to Regulatory Approvals 22 AML or MDS CR and M RD positive Not eligible for MAC Randomized 2 - arm (n ~ 200) JSP191 + Flu/TBI Flu/TBI vs. Trial could open in 2022 JSP191/Flu/TBI vs. Flu/TBI Superiority Trial Eggimann L, et al. 2015 A
Slide 23: JSP191 Autoimmune Study
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 Autoimmune Study: A Study in Patients with Severe Autoimmune Diseases 23 JSP191 in combination with a reduced intensity conditioning regimen for allo - HCT SAFETY RUN - IN DOSE EXPANSION COHORT PRIMARY OBJECTIVE EFFICACY ENDPOINTS Safety Engraftme
Slide 24: JSP191 Targets a Large Addressable Market Across Multiple Diseases
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Allo - HCT for Heme Malignancies Allo - HCT for Non - Malignant Disease Autologous Gene Therapy JSP191 Targets a Large Addressable Market Across Multiple Diseases Treated by Stem Cell Transplant 24 Severe / Refractory Autoimmune ~$2B MARKET TRANSPLANTS ~
Slide 25: Jasper eHSC Platform: Unlocking the Potential of Stem Cells
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Jasper Engineered Hematopoietic Stem Cells ( eHSC ) Platform: Unlocking the Potential of Stem Cells Jasper eHSCs mRNA Engineering Replete / Modified Grafts Patient stem cells Unmodified donor stem cells Engineered stem cells UNMODIFIED DONOR STEM CELLS E
Slide 26: Jasper eHSCs: Single Designer Receptor Can Confer Significant Advantage
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Jasper eHSCs : Addition of a Single Designer Receptor Can Confer Significant Advantage to Curative Stem Cells 26 1. CD117 manipulation to convey an intrinsic proliferative advantage 2. CD117 manipulation to enable resistance to JSP191 conditioning 3. New
Slide 27: CD117 Manipulation to Convey Intrinsic Proliferative Advantage
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL 1. CD117 manipulation to convey an intrinsic proliferative advantage Proof of Concept: JSP - 502 Reprograms Cells to SCF Independence and Faster Growth than CD117 Dependent Cells Clinical Hypothesis: JSP - 502 Engineered HSCs Will Outcompete Normal HSCs
Slide 28: CD117 Manipulation to Enable Resistance to JSP191 Conditioning
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL 2. CD117 manipulation to enable resistance to JSP191 conditioning Transient RNA expression enables JSP191 resistance Proof of Concept: JSP - 502 Reprogrammed Cells are Resistant to JSP191 Inhibition Clinical Hypothesis: JSP - 502 Engineered HSCs Can Be G
Slide 29: mRNA Insertion into CD34+ Stem Cells with Efficiency and Viability
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Viability & Efficiency mRNA Insertion into CD34+ Stem Cells with Efficiency and Viability 29 78% 22% Viability 98% 2% Efficiency Next Steps mRNA Insertion GFP mRNA inserted into HSCs via electroporation • In vitro functional assays pending to evaluate he
Slide 30: eHSCs Aim to be Broadly Applicable Across Patient Populations
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Allo - HCT for non - malignant heme Auto gene therapy for beta - thal + SCD Severe / refractory autoimmune eHSCs Aim to be Broadly Applicable Across Patient Populations with Unmet Need and Large Addressable Markets 30 x Improved safety x Improved engraft
Slide 31: Jasper Expected Milestones
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Jasper Expected Milestones • Q2 2021 – JSP191 AML/MDS Phase 1a top line 90 - day data • Q2 2021 – JSP191 AML/MDS open enrollment of Phase 1b expansion • Q4 2021 – JSP191 Autoimmune IND filing for Phase 1a pilot study • Q4 2021 – Engineered Stem Cell Plat
Slide 32: Appendix
CONFIDENTIAL Appendix April 2021
Slide 33: JSP191 HCT Conditioning Poised to Transform HCT to Cure Severe Autoimmune Diseases
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 HCT Conditioning Poised to Transform HCT to Cure Severe Autoimmune Diseases 33 JSP191 + Modified Graft LUPUS 15,000 + SCLERODERMA 50,000+ MS 50,000+ Disease Modification vs. DMARDs Pilot Study Initiation Targeted for 2H of 2021 JSP191 therapy has
Slide 34: HSCT is a Multi-Step Procedure Resulting in Curative Cellular Replacement
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Hematopoietic Stem Cell Transplantation is a Multi - Step Procedure Resulting in Curative Cellular Replacement 34 Patient Conditioning Before Transplant Healthy Donor or Gene Therapy Stem Cells Transplanted into Patient • Conditioning with radiation and
Slide 35: Toxic Conditioning Regimens is an Obstacle for Transplant
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Toxic Conditioning Regimens is an Obstacle for Transplant: Jasper is Developing a Safer Alternative 35 Conditioning with radiation and chemotherapy is required to prepare the body to accept new donor cells Toxicities include damage to collateral organs i
Slide 36: Busulfan is Carcinogenic and Broadly Toxic Across Multiple Organ Systems
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Busulfan is Carcinogenic Via Direct Nucleoside Alkylation and Broadly Toxic Across Multiple Organ Systems Alkylating agents (e.g., busulfan, melphalan) cause random DNA damage throughout the genome • During the DNA repair process, there is frequent misre
Slide 37: Different Clinical Settings May Require Different Levels of Chimerism
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Different Clinical Settings May Require Different Levels of Chimerism for Therapeutic Benefit 37 Donor Chimerism SCID ~5% ß - thalassemia >10% Autoimmune Disease and Tolerance >60% AML,MDS, ALL >95% + Disease Eradication 100% 50% 0% SCD > 4 - 20% Fitzhug
Slide 38: JSP191 Preclinical POC as Single Agent for HSC Depletion
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 Preclinical POC as Single Agent for HSC Depletion: JSP191 Causes Robust And Transient Depletion Of BM HSC in Non - Human Primates 38 Anti - human CD117 antibody - mediated bone marrow niche clearance in non - human primates and humanized NSG mice
Slide 39: Other Anti-CD117 Antibodies Do Not Deplete HSCs as a Single Agent
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Other Anti - CD117 Antibodies Do Not Deplete HSCs From the Bone Marrow as a Single Agent In - Vivo 39 Control Magro - limab Anti - CD117 (FSI - 174) 0.3 1 3 Percent Change in HSC Frequency Percent Change in HSC Frequency MGTA - 117 Naked Anti - CD117 FSI
Slide 40: JSP191 Validated in Multiple Disease Models
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 Validated in Multiple Disease Models Where HSC is Standard Curative Therapy 40 Demonstrated robust pre - clinical data in multiple models of transplant and disease • Disease: SCID, AML, MDS, Sickle Cell • Transplant: Mouse, Non - human primate Con
Slide 41: JSP191 Targets and Depletes Disease Initiating Stem Cells in MDS/AML
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. 41 JSP191 Targets and Depletes Disease Initiating Stem Cells in MDS/AML Anti - CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice Wendy W. Pang, Agnieszka Czechowicz , Aaron C. Logan, Rashmi Bha
Slide 42: Anti-CD117 Validated in Multiple Disease Models (MDS Mouse Model)
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Anti - CD117 Validated in Multiple Disease Models Where HSC is Standard Curative Therapy 42 Severe combined immunodeficiency (SCID) Hematologic Cancers (AML, MDS) Sickle Cell Disease Anti - CD117 Depletes MDS HSC and Synergizes With Low Dose Radiation To
Slide 43: Anti-CD117 Validated in Multiple Disease Models (Sickle Cell)
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Anti - CD117 Validated in Multiple Disease Models Where HSC is Standard Curative Therapy 43 Anti - CD117 conditioning + transplant leads to normalization of hemoglobin in sickle cell model Myeloid Chimerism Hemoglobin 0 10 20 30 40 50 % D o n o r M a c 1
Slide 44: Anti-CD117 Ab Unique MOA: Synergy With Low Dose Radiation
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Anti - CD117 Ab Unique MOA: Synergy With Low Dose Radiation To Allow Engraftment Equivalent to High Dose Radiation 44 Chhabra et al. Sci Transl Med 8:351, 2016/ Poyser , unpublished Radiation only Anti - CD117 + Low Dose Radiation Stem Cell
Slide 45: Anti-CD117 + 5-Aza Enables HSC Engraftment in Sickle Cell Model
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Anti - CD117 Validated in Multiple Disease Models Where HSC is Standard Curative Therapy 45 Anti - CD117 + 5 - Aza Enables HSC E ngraftment in Inflamed Sickle Cell Model Severe combined immunodeficiency (SCID) Hematologic Cancers (AML, MDS) Sickle Cell D
Slide 46: JSP191 + Azacytidine Combination For Non-Radiation Outpatient Conditioning
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 + 5 - Azacytidine Combination For Deep Non - Radiation Based Outpatient Conditioning 46 ▪ New data showing synergistic effect of SCF blockade + 5 - azacytidine on stem cell engraftment (Stanford) ▪ Widely available Sub - q / IV generic currently u
Slide 47: JSP191 SCID Study Safety and Tolerability Leading to FDA Amendment
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 SCID Study Safety and Tolerability Leading to FDA Amendment Allowing for Outpatient Study • No significant infusional toxicities observed • No antibody related toxicity • No myelosuppression • Re - transplant p atients can be discharged 48 hrs aft
Slide 48: JSP191 Could Expand Use of Curative Transplant in AML/MDS
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Years Post HCT Low dose High dose Disease Free Survival p = 0.02 JSP191 Could Expand Use Curative Transplant in AML / MDS by Delivering a Less Toxic, Efficacious Conditioning Regimen • Due to toxicities, full dose conditioning is reserved for younger and
Slide 49: Conversion to MRD Negative Status Correlates with Longer Survival
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Successful Conversion to MRD Negative Status Post - Allogeneic Transplant Correlates with Longer Survival in MDS Patients • Post - transplant survival / relapse is predicted by measurement of residual disease (MRD) • Patients with MRD mutation frequency
Slide 50: MDS/AML Subject Demographics
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. MDS/AML Subject Demographics (detailed) 50 Subject Number Age Sex Diagnosis Prior Therapy for MDS or AML Med History Donor 003 74F T - AML Azacitidine / Venetoclax • Breast Cancer with recurrence treated with Chemotherapy and Radiation therapy • Hypothyr
Slide 51: JSP191 PK at 0.6 mg/kg Consistent Among AML/MDS Subjects
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 PK at 0.6 mg/kg was Observed to be Consistent Among AML/MDS Subjects (N = 6) 51 71.0 hours Observed half - life 10 - 12 days Clearance time to donor graft infusion Muffly et al, TCT2021 Late Breaking abstract (#LBA5)
Slide 52: JSP191 AML/MDS Neutrophil Recovery
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 AML/ MDS Neutrophil Recovery 52 Subject Number Screening ANC 1 (k/ uL ) 0003 0.1 0004 0.5 0005 0.07 0009 2.93 0010 1.2 0011 4.14 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 -20 -10 0 10 20 30 40 50 60 ANC (k/uL) Time Relative to Transplant Day 0 Absolute Neut
Slide 53: JSP191 AML/MDS Study Chimerism to 90 days
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 AML / MDS Study Chimerism to 90days 53 Table data reflected in graphs: A : Total cell chimerism, B: CD15+ Myeloid Cell Chimerism, C: CD3+ T Cell Chimerism, D: CD56 NK Cell Chimerism. Subject Number Donor Chimerism at TD+28 Donor Chimerism at TD+56
Slide 54: MDS/AML: Elimination of MRD Suggests Successful Targeting of Diseased Stem Cells
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL MDS/AML: Elimination of MRD Suggests Successful Targeting of Diseased Stem Cells using JSP191/TBI/Flu (Biomarker for Positive Outcomes) Subject Number MRD at Screening MRD at TD+28 MRD at TD+56 MRD at TD+90 NGS, Flow, or Cyto NGS, Flow, or Cyto NGS, Flow
Slide 55: JSP191 Total Donor Chimerism vs. TBI/Flu Alone
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 Total Donor Chimerism at Day 90 vs. TBI/Flu Alone 55 JSP191 + TBI/Flu (Jasper) TBI/Flu Alone 62% of patients demonstrated full chimerism after RIC with 2 Gy TBI/Flu 1 Eggimann L, Girsberger S, Halter J, et al. Kinetics of peripheral blood chimeris
Slide 56: After RIC with TBI/Flu, 38% Patients Fail to Demonstrate Full Chimerism
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL After RIC with TBI/Flu, 38% Patients Fail to Demonstrate Full Chimerism, Which Predicts Significantly Worse Survival 56 Source: Eggimann L, Girsberger S, Halter J, et al. Kinetics of peripheral blood chimerism for surveillance of patients with leukemia a
Slide 57: JSP191 Total Donor Chimerism vs. Regimens Containing RIC Busulfan
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 Total Donor Chimerism at Day 90 vs. Regimens Containing RIC Busulfan 57 JSP191 + TBI/Flu (Jasper) RIC Busulfan (Dana Farber 1 ) ~20% of patients failed to achieve >90% total donor chimerism by Day 100 1 1 Koreth J, Kim HT, Nikiforow S, et al. Dono
Slide 58: ~80% Achieve >90% Donor Chimerism After RIC Busulfan
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL ~80% Achieve >90% Donor Chimerism After RIC Busulfan Which is Associated with PFS and Survival 58 Source: Koreth J, Kim HT, Nikiforow S, et al. Donor chimerism early after reduced - intensity conditioning hematopoietic stem cell transplantation predicts
Slide 59: JSP191 Development Starts with AML/MDS Patients Not Eligible for Myeloablative Transplant
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 Development Starts with AML/ MDS Patients Not Eligible for Myeloablative Transplant and Expands Across Hematological Malignancies 59 JSP191 Development in AML/MDS and Other Heme Malignancies MRD - positive AML/MDS patients not eligible for myeloab
Slide 60: Potential JSP191 Paths to Registration for AML/MDS
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Potential JSP191 Paths to Registration for AML/ MDS Patients Not Eligible for Myeloablative Transplant 60 JSP191 0.6mg/kg in combination with low dose fludarabine and TBI Potential Endpoints: Complete Response 18 - month Relapse - Free Survival 18 - mont
Slide 61: JSP191 Would Be Clinically and Financially Beneficial for Hospitals
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. JSP191 Would Be Both Clinically and Financially Beneficial for Hospitals 61 Adjusted MS - DRG 014 Payment - Jasper AlloHCT Hospital Costs = IP Income - 9 - 8 - 7 - 6 - 5 - 4 - 3 - 2 - 1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Jasper method Comp
Slide 62: JSP191 Intellectual Property and Exclusivity
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 Intellectual Property and Exclusivity 62 • Amgen: WW license on molecule and COM IP • Stanford: IP on use as conditioning agent, combinations, dosing • Regulatory exclusivity expected to 2036
Slide 63: JSP191 CMC
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL JSP191 CMC 63 • CMC process successfully transferred from Amgen to Lonza • First Lonza drug substance batch run at commercial scale and released at GMP • Initial pilot scale biochemical comparability complete, commercial scale comparability ongoing • Val
Slide 64: Competitive Landscape: JSP191 Highly Differentiated Anti-CD117 Antibody
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Competitive Landscape: JSP191 is a Highly Differentiated, First - in - Class Anti - CD117 Antibody for Transplant Conditioning 64 Program JSP191 Anti - CD117 mAb LOP628 Anti - CD117 ADC (TERMINATED) GS - 0174 Anti - CD117 MGTA - 117 Anti - CD117 ADC CDX
Slide 65: Targeted Busulfan Conditioning Still Results in Significant Toxicities
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Targeted Busulfan Conditioning Still Results in Significant Toxicities • No demonstrated benefit in infertility – “infertility risk from Busulfan in gene therapy continues to be studied” • median 74.4 mg*h/L 1 65
Slide 66: Toxin Linked CD117 Approaches Have Significant Challenges
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Toxin Linked CD117 Approaches Have Significant Challenges With Off - Target Toxicity, Manufacturing and Development JSP191 specifically depletes Stem Cells • JSP191 blocks SCF survival signal on Stem Cells • MOA synergistic with radiation, azacytidine, C
Slide 67: JSP191 vs. MGTA-117 in NHP Model
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL NHP # - AMG 191 dose HSC depletion day 7 HSC depletion day 10 #1 0.1 mg/kg 71% 94% #2 0.1 mg/kg 96% 86% #3 1.0 mg/kg 79% 78% #4 1.0 mg/kg 94% 97% CD34 + CD90 + HSC Depletion in NHP after JSP191 JSP 191 Magenta Anti - CD117 ADC JSP191 vs. MGTA - 117 in NH
Slide 68: MGTA-117 Will Require Additional Therapies for Allogeneic Transplant
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL MGTA - 117 Will Require Additional Therapies for Allogeneic Transplant 68 Depletion of patient’s T - cells is required for allogeneic transplant • Patient’s T - cells will attack donor graft, leading to graft failure • Current strategies include: TBI + f
Slide 69: Jasper's eHSCs Will Drive Cures, Decrease Toxicity, Eliminate Immune Suppression
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL We Believe Jasper’s Engineered Hematopoietic Stem Cells ( eHSCs ) Will Drive Cures, Decrease Toxicity, and Eliminate Post Transplant Immune Suppression 69 • Primary human CD34+ cell experiments with multiple engineering approaches • Preclinical proof of
Slide 70: eHSCs Improve Donor Stem Cell Engraftment From Donation to Recovery
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Jasper Engineered Hematopoietic Stem Cells ( eHSCs ) Improve Donor Stem Cell Engraftment From Donation to Recovery 70 1. Stem Cells Harvested 2. Conditioning 3. Transplant The picture can't be displayed. 4. Post - HCST Recovery x Increased utility for ha
Slide 71: Stem Cell Engineering: Only Jasper eHSC Designed to Increase Engraftment
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Stem Cell Engineering: Only Jasper eHSC Designed to Increase Stem Cell Engraftment and Proliferation 71 Program Jasper eHSCs VOR33 (CD33) Hypoimmune Technology In Vivo Gene Therapy Competitive positioning • Cellular engineering leading to improved donor
Slide 72: Competitive Landscape: CD45 Targets Require Toxic or Radioactive Payloads
© 2021 Jasper Therapeutics, Inc. CONFIDENTIAL Competitive Landscape: CD45 Targets Require Toxic or Radioactive Payloads Which Limit Safety as well as Ability to Manufacture/Distribute 72 Program Iomab - B CD45 antibody radiation conjugate MGTA - 145 CD45 ADC CD45 ETB Engineered toxin bodies Competit
Slide 73: Jasper's Success May Lead to Routine Stem Cell Transplants
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Jasper’s Success May Lead to Routine Hematopoietic Stem Cell Transplants For Hundreds of Thousands of Patients 73 2021 TODAY 2028 JSP191 + Jasper eHSCs • JSP191 safe outpatient conditioning • Jasper eHSCs for improved transplant without hospitalization o
Slide 74: Risk Factors
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Risk Factors 74 The list below of risk factors has been prepared solely for purposes of the proposed private placement transaction (the “Priv ate Placement”) as part of the proposed business combination (the “Business Combination”) of Amplitude Healthcar
Slide 75: Risk Factors (cont'd): Regulatory Regime for Product Candidates
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Risk Factors (cont’d) 75 Risks Related to the Regulatory Regime for Jasper’s Product Candidates Jasper has no experience as a company in obtaining regulatory approval for a drug. The regulatory landscape that will govern Jasper’s product candidates is un
Slide 76: Risk Factors (cont'd): Intellectual Property
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Risk Factors (cont’d) 76 Risks Related to Jasper’s Intellectual Property Jasper’s commercial success depends on its ability to obtain, maintain and protect its intellectual property and proprietary tec hnology. The patent protection Jasper obtains for it
Slide 77: Risk Factors (cont'd): Risks Related to the Private Placement
CONFIDENTIAL © 2021 Jasper Therapeutics, Inc. Risk Factors (cont’d) 77 Risks Related to the Private Placement AMHC may be unable to raise sufficient capital in the Private Placement or otherwise obtain additional financing to complete the Business Combination or to fund the operations and growth of